Clinical Research
The science is in.
It works.
Sublingual ketamine treatment is backed by independent peer-reviewed research and real-world data from thousands of patients across published studies. Here's what that research shows
Statistics reflect findings from independently conducted, peer-reviewed studies cited below and are not based on Leven Health's own clinical data unless otherwise noted.
Off-label use. Ketamine is not FDA-approved for depression, anxiety, or PTSD.
Telehealth Delivery
The evidence holds up
no matter where care happens
Two independent, peer-reviewed datasets — including the largest ever published on the subject — show that ketamine delivered via telehealth produces outcomes comparable to in-clinic IV treatment.
The largest prospective telehealth trial of its kind
In this trial, nearly two-thirds of participants treated entirely through telehealth felt meaningfully better, with results on par with in-clinic IV ketamine.⁴ A separate independent real-world dataset of thousands of patients confirmed similarly consistent results using machine-learning analysis — not just findings from a single study. ³
Conditions
All studies referenced are peer-reviewed and published in indexed medical journals, conducted independently by outside researchers and not affiliated with or funded by Leven Health. Statistics reflect outcomes for sublingual or transmucosal ketamine specifically, not IV infusion. Individual results may vary.
[1] Lara, D.R., et al. (2013). International Journal of Neuropsychopharmacology
[2] Hassan, A., et al. (2022). Frontiers in Psychiatry
[3] Mathai, D.S., et al. (2024). Journal of Affective Disorders
[4] Hull, T.D., et al. (2022). Journal of Affective Disorders
[5] Francis (2025). Cureus
[6] Beaglehole, B., et al. (2025). Journal of Psychopharmacology
[7] Hartberg, J., et al. (2018). Psychopharmacology
